bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.11.10.515995

The usage of transcriptomics datasets as sources of Real-World Data for clinical trialling

Abstract

BackgroundRandomised Clinical Trials (RCT) reflect results within their specific controlled settings, necessitating further studies to understand outcomes across all possible scenarios. The usage of Real-World Data (RWD) has been recently considered to be a viable alternative to overcome these issues and complement clinical conclusions. Molecular profiles of patients captured by high-throughput measures reflect their medical conditions. When this information is linked to clinical and demographical information, nuances in transcriptomics data can uncover subtle variations in disease pathways among distinct patient groups. This work focuses on the construction of a patient repository database with molecular and clinical information resulting from the integration of publicly available transcriptomics datasets. ResultsPatient data were integrated into the patient repository by using a novel post-processing technique allowing for the usage of samples originating from different/multiple Gene Expression Omnibus (GEO) datasets. Our post-processing technique, which we have named MicroArray Cross-plAtfoRm pOst-prOcessiNg (MACAROON), aims to standardise and integrate transcriptomics data (considering batch effects and possible processing-originated artefacts). This process was able to better reproduce the down streaming biological conclusions in a 45% improvement compared to other methods available. Furthermore, RWD was mined from GEO samples metadata and a clinical and demographical characterisation of the database was obtained. RWD mining was done through a manually curated synonym dictionary allowing for the correct assignment (95.33% median accuracy; 80.14% average) of medical conditions. ConclusionsOur strategy produced a repository, which includes molecular, clinical and demographical RWD by integrating multiple public datasets. The exploration of these data facilitates the discovery of clinical outcomes and molecular pathways specific to predetermined patient populations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Matos-Filipe, P., Garcia-Illarramendi, J. M., Jorba, G., Oliva, B., Farres, J., Mas, J. M.. 2022-11-13. The usage of transcriptomics datasets as sources of Real-World Data for clinical trialling. https://doi.org/10.1101/2022.11.10.515995

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Uncovering Viral Signals Across Cell Populations in Colorectal Cancer

Viral sequences have been detected in colorectal cancer, but their cellular and anatomical distribution remains poorly resolved. We aimed to establish a cell-type-resolved map of viral reference-associated RNA signals across colorectal cancer, tumour-adjacent normal tissue, and healthy colon. We repurposed human-unmapped reads from single-cell RNA sequencing libraries generated in ten publicly available studies. We retained cell-barcode and unique molecular identifier information, removed duplicate molecules, and aligned reads to a curated human-associated viral reference using three aligners. Viral signals were analysed across cell types, tissue conditions, and colorectal segments. We used participant-grouped repeated cross-validation to evaluate tissue-condition classification and screened an independent paired colorectal cancer proteomics cohort for compatible peptide matches. The study included 547 libraries from 112 participants, including 49 with matched colorectal cancer and tumour-adjacent normal samples, and approximately 415,000 cells spanning ten major cell populations. Viral reference-associated RNA signals differed across epithelial, immune, stromal, and vascular compartments, tissue conditions, and anatomical regions of the colon. Of 318 independent healthy-reference viral-load comparisons, seven involving six virus-cell-type groups remained significant after Benjamini-Hochberg correction, including plasma-cell HHV-7 and HHV-6B and mast-cell HCV-2. Cell-type-resolved viral features distinguished colorectal cancer, tumour-adjacent normal tissue, and healthy colon in participant-grouped validation; random forest achieved a macro-AUC of 0.957 (SD 0.028), with HERV-K113 as the leading quantitative feature. An independent proteomic screen identified peptide matches compatible with 20 candidate viral groups. We established a cell-type-resolved map of viral reference-associated RNA signals across colorectal tissue conditions and anatomical regions. By identifying candidate viral signals in epithelial and immune compartments, this map provides a basis for investigating virus-host pathways involved in tumour biology, immune regulation, and antigen-presentation states, and could help prioritise future combination strategies pairing virus-directed or virus-mimetic approaches with standard treatment or immune checkpoint blockade.

bioinformatics↗

Statistical significance testing for spatial domain detection in spatial transcriptomics

In spatial transcriptomics, domain-detection methods group platform-specific spatial measurement units--cells, bins or multicellular spots--into spatial domains for comparing molecular programs, cellular composition and interactions among tissue regions. However, the number of candidate domains detected in the same tissue can vary with user-specified parameters or model-selection criteria. Whether candidate domains should be merged can be framed as a test of a single-domain null hypothesis, under which each gene has constant mean expression across all spatial units in the combined region. However, testing candidate domains on the same gene-expression data used to detect them may induce post-selection bias and yield anti-conservative p-values, increasing the risk of oversegmentation. To address these challenges, we introduce SigDoTS (statistical Significance testing for Domain deTection in Spatial transcriptomics), a hypothesis-testing framework for spatial domain detection. SigDoTS uses hierarchical testing to determine which candidate domains to retain or merge, with adjustment for family-wise error control. It accounts for gene-gene covariance and spatial dependence and computes p-values by rerunning the upstream domain-detection pipeline on datasets simulated under the fitted single-domain null. In simulations, SigDoTS controlled the type I error rate at the root node under the single-domain null and improved recovery of the true spatial domains when multiple domains were present. In human dorsolateral prefrontal cortex, SigDoTS retained superficial and deep Layer 6 domains but merged Layer 3 candidate domains across different initial numbers of candidate domains. In ovarian and colorectal cancers, SigDoTS retained epithelial domains with different gene-expression programs and local immune environments, together with immune, stromal and vascular domains.

bioinformatics↗

ASD Neuro Agentic (ANA): An Agentic Framework for Feature Discovery and Cross Site Generalization in Autism fMRI Classification

Classifiers of autism spectrum disorder (ASD) from resting state functional MRI rarely generalize across sites, and many reported accuracies are inflated by data leakage.We show that an agentic artificial intelligence framework, ASD Neuro Agentic (ANA), whose language model agents propose features from the literature and researcher input while fixed tools perform every calculation, can search auditably for site independent classifiers while controlling the leakage. In 1,028 participants from 17 ABIDE I centers, ANA tested 71 pipelines and selected a ComBat harmonized ensemble of tangent space connectivity models from six parcellations and 98 public connectivity derivatives. In leave one center out testing, the ensemble reached an area under the curve of 0.814 (95% CI, 0.773 to 0.841), outperforming ASD DiagNet and ASD SAENet. Predictive connectivity was mainly reduced in ASD. Agentic AI offers a systematic and efficient approach to exploring, evaluating, and identifying pipelines as model selection grows complex.

bioinformatics↗